Inflammatory bowel disease (IBD), with its two main disease entities Crohn's disease and ulcerative colitis, is a chronic and relapsing inflammation of the gastrointestinal tract. The highest prevalence of IBD is found in ...
Jan 20, 2022
0
6
The COVID-19 pandemic was associated with a 60 percent decrease in the number of launches of oncology clinical trials of drugs and biologic therapies, according to a research letter published online Jan. 27 in JAMA Network ...
Feb 4, 2021
0
2
(HealthDay)—In a new clinical guideline from the American Gastroenterological Association, recently published in Gastroenterology, treatment recommendations are presented for patients with moderate-to-severe ulcerative ...
Mar 4, 2020
0
2
The utilization of stem cell therapies for augmentation of tissue healing has far outpaced the supporting scientific and clinical data, largely due to aggressive marketing that has led to widespread and often inappropriate ...
Oct 1, 2019
0
2
In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. ...
Sep 27, 2019
0
7
(HealthDay)—In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 ...
Mar 28, 2019
0
3
(HealthDay)—Potential side effects of biological agents may increase anxiety in patients with rheumatic disease, according to research published in the June issue of the International Journal of Rheumatic Diseases.
Aug 21, 2018
0
5
A new study, published today in Nature Structural and Molecular Biology, moves researchers closer to understanding one of the crucial proteins involved in Parkinson's disease.
Jul 4, 2018
0
6
(HealthDay)—Patients with psoriasis may have a higher risk of melanoma and hematologic cancers than the general population, according to a study published in the April issue of the Journal of the American Academy of Dermatology.
Mar 28, 2017
0
25
Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to ...
Dec 1, 2016
0
4
